Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: ROMAINE INVESTIGATION UPDATE: #FDA and @CDCgov have identified one source for the E. coli romaine outbreak as the r… https://t.co/Kks8vmPi1J
SteveFDA (R-D.C.)
@SGottliebFDA
Working quickly with #CDC and state partners allowed us to efficiently find one source of the outbreak. Romaine lettuce will now be labeled on store shelves with the date and harvest origin, making it easier for us to give targeted info regarding future outbreaks.
SteveFDA (R-D.C.)
@SGottliebFDA
FDA continues to focus on approving high-quality, lower cost, safe & effective generics - In Nov. FDA approved & tentatively approved 128 generic drugs - with 13 first generics for brands that lacked competition & 20 complex generics https://t.co/PTxhJIE5Zw
SteveFDA (R-D.C.)
@SGottliebFDA
The NECC case is a tragic reminder of why compounding and compounded drugs can present serious risks. #FDA has taken significant steps to ensure the quality of compounded drugs and improve patient safety in order to prevent another calamity like this https://t.co/I2x0SGwYPQ
SteveFDA (R-D.C.)
@SGottliebFDA
We do not want to see another tragedy like the one we saw in 2012. FDA will continue taking steps to promote quality products for consumers who rely on compounded drugs https://t.co/I2x0SGwYPQ
SteveFDA (R-D.C.)
@SGottliebFDA
Over the past 2 years #FDA has approved record numbers of generic drugs: Nov 2018 had the same number of approval actions as record-breaking Oct, which was highest ever in a single month - a total of 128. We’ll continue our efforts to increase competition https://t.co/PTxhJIE5Zw https://t.co/9ptGPi4Bf8
SteveFDA (R-D.C.)
@SGottliebFDA
@BlumenthalG @pkluetz @tmprowell Couldn’t leaf it alone. I’m green with envy over the wit and charm!
SteveFDA (R-D.C.)
@SGottliebFDA
RT @CDCDirector: Influenza activity will increase and is likely to peak during December-February. Protect yourself against the #flu… https://t.co/7Zr66vgiLJ
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: OMB Director Mick Mulvaney has been a principled partner to the #FDA and deeply public health minded in all of his engage… QT @MickMulvaneyOMB: This is a tremendous honor. I look forward to working with the President and the entire team. It’s going to be a gr… https://t.co/ee0Odre2Ma)
SteveFDA (R-D.C.)
@SGottliebFDA
We’re also eager to work with Congress on a new framework that would give the FDA more ability to update old generic labels, an idea that was proposed by Senators Hatch and Bennet and advanced by others including @CancerResrch https://t.co/aivxZY4rZa
SteveFDA (R-D.C.)
@SGottliebFDA
OMB Director Mick Mulvaney has been a principled partner to the #FDA and deeply public health minded in all of his engagements with us; and we are absolutely delighted to have the opportunity to work with Mr. Mulvaney in this important new role. QT @MickMulvaneyOMB: This is a tremendous honor. I look forward to working with the President and the entire team. It’s going to be a gr… https://t.co/ee0Odre2Ma)
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAOncology: #FDADISCO hosts Dr Abhi Nair & Dr Sanjeeve Bala talk about cancer drug approvals at https://t.co/bYTWyABy8q or on i… https://t.co/9EsaDRzJnv
SteveFDA (R-D.C.)
@SGottliebFDA
Unlike small molecule drugs made from chemicals, biologics are generally large, complex molecules that may be derived, through biotechnology, from a living system such as a microorganism or a plant or animal cell. https://t.co/vp3Pw9lals
SteveFDA (R-D.C.)
@SGottliebFDA
FDA Withdraws Proposed Rule That Would Have Exposed Generic-Drug Makers to Liability - WSJ https://t.co/SYSpHfvzC2
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: Our goal is to facilitate and streamline the patient experience with our expanded access program; to create concie… https://t.co/cksz0Q1IIq
SteveFDA (R-D.C.)
@SGottliebFDA
Our goal is to facilitate and streamline the patient experience with our expanded access program; to create concierge-like service for providers and patients who are trying to get access drugs. We want to make the entire process more efficient and robust. https://t.co/IJwF1Mtw1p
SteveFDA (R-D.C.)
@SGottliebFDA
Therapeutic biologics play a critical role in the treatment of many serious illnesses and are responsible for a significant percent of rising drug prices. Today’s #FDA #SundayTweetorial is about what FDA is doing to improve patient access to insulin and other essential medicines. https://t.co/XT4dydqBUb
SteveFDA (R-D.C.)
@SGottliebFDA
About one out of every three new drugs approved by the FDA is a biologic but they accounted for 70 percent of the growth in drug spending from 2010 to 2015, according to a study conducted by the RAND Corp. https://t.co/Ipu4DAxjhB.
SteveFDA (R-D.C.)
@SGottliebFDA
Competition drives prices lower. The 1984 Hatch Waxman Act created an abbreviated path to market for generic versions of drugs. Today, generics account for 90% of the scripts written, saving patients about $1 trillion over the past decade.
SteveFDA (R-D.C.)
@SGottliebFDA
Examples include monoclonal antibodies (targeted therapies for cancer & other diseases), cytokines involved in immune response, growth factors that affect cell growth, and enzymes that speed up biochemical reactions https://t.co/Liah9AAoDx. https://t.co/xO1cKQGmRO